Notably, the total level of m6A modification depends on the dynamic balance between methyltransferase “writers” and demethylase “erasers.” In our study, the expression of METTL3 decreased after Aβ treatment, while other “m6A writers” or “m6A erasers” showed no variations, which was similar to the results in AD patients (Huang et al., 2020; Zhao et al., 2021). This evidence concerns the gene MBD2 and Alzheimer disease.